|
1
|
Nakashima K, Zhou X, Kunkel G, Zhang Z,
Deng JM, Behringer RR and de Crombrugghe B: The novel zinc
finger-containing transcription factor osterix is required for
osteoblast differentiation and bone formation. Cell. 108:17–29.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsubara T, Kida K, Yamaguchi A, Hata K,
Ichida F, Meguro H, Aburatani H, Nishimura R and Yoneda T: BMP2
regulates Osterix through Msx2 and Runx2 during osteoblast
differentiation. J Biol Chem. 283:29119–29125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koga T, Matsui Y, Asagiri M, Kodama T, de
Crombrugghe B, Nakashima K and Takayanagi H: NFAT and Osterix
cooperatively regulate bone formation. Nat Med. 11:880–885. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao Y, Zhou Z, de Crombrugghe B, Nakashima
K, Guan H, Duan X, Jia SF and Kleinerman ES: Osterix, a
transcription factor for osteoblast differentiation, mediates
antitumor activity in murine osteosarcoma. Cancer Res.
65:1124–1128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Logothetis CJ and Lin SH: Osteoblasts in
prostate cancer metastasis to bone. Nat Rev Cancer. 5:21–28. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schägger H and von Jagow G: Tricine-sodium
dodecyl sulfate-polyacrylamide gel electrophoresis for the
separation of proteins in the range from 1 to 100 kDa. Anal
Biochem. 166:368–379. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang D, Guo Q, Guo Y, Peng Y and Ma C:
Expression of osterix in metastatic breast cancer cells and its
effects on MMP-2, MMP-9 and VEGF promoter activities. Suzhou
University Journal of Medical Science. 3:62010.
|
|
9
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grigoryan T, Wend P, Klaus A and
Birchmeier W: Deciphering the function of canonical Wnt signals in
development and disease: Conditional loss- and gain-of-function
mutations of beta-catenin in mice. Genes Dev. 22:2308–2341. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferrara N, Gerber H and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zebrowski BK, Yano S, Liu W, Shaheen RM,
Hicklin DJ, Putnam JB Jr and Ellis LM: Vascular endothelial growth
factor levels and induction of permeability in malignant pleural
effusions. Clin Cancer Res. 5:3364–3368. 1999.PubMed/NCBI
|
|
13
|
Zebrowski BK, Liu W, Ramirez K, Akagi Y,
Mills GB and Ellis LM: Markedly elevated levels of vascular
endothelial growth factor in malignant ascites. Ann Surg Oncol.
6:373–378. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berns EM, Klijn JG, Look MP,
Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen
H, van Staveren IL, Meijer-van Gelder ME, et al: Combined vascular
endothelial growth factor and TP53 status predicts poor response to
tamoxifen therapy in estrogen receptor-positive advanced breast
cancer. Clin Cancer Res. 9:1253–1258. 2003.PubMed/NCBI
|
|
15
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Curran S and Murray GI: Matrix
metalloproteinases: Molecular aspects of their roles in tumour
invasion and metastasis. Eur J Cancer. 36:1621–1630. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hoekstra R, Eskens FA and Verweij J:
Matrix metalloproteinase inhibitors: Current developments and
future perspectives. Oncologist. 6:415–427. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Niwa H, Tsuneyama K and Takano Y: Expressions of MMP-2,
MMP-9 and VEGF are closely linked to growth, invasion, metastasis
and angiogenesis of gastric carcinoma. Anticancer Res.
26:3579–3583. 2006.PubMed/NCBI
|
|
20
|
Sier CF, Kubben FJ, Ganesh S, Heerding MM,
Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB and Verspaget
HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are
related to the overall survival of patients with gastric carcinoma.
Brit J Cancer. 74:4131996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liabakk N, Talbot I, Smith RA, Wilkinson K
and Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix
metalloprotease 9 (MMP-9) type IV collagenases in colorectal
cancer. Cancer Res. 56:190–196. 1996.PubMed/NCBI
|
